INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2009

Oral ketogenic agent AC-1202 elevated serum ketones and improved ADAS-Cog scores compared with placebo in patients with mild to moderate Alzheimer's disease.

A 90-day randomized, double-blind, placebo-controlled trial evaluated daily administration of the ketogenic compound AC-1202 in 152 patients with mild to moderate Alzheimer's disease who maintained a normal diet. AC-1202 significantly elevated serum beta-hydroxybutyrate 2 hours post-dose. Compared to placebo, AC-1202 led to a significant difference in mean change from baseline in ADAS-Cog score at Day 45 across the ITT (1.9-point difference, p = 0.0235), per-protocol (2.53-point difference, p = 0.0324), and dosage-compliant (2.6-point difference, p = 0.0215) groups. Improvements were most pronounced in APOE4-negative subjects, showing significant ADAS-Cog differences at both Day 45 and Day 90. Adverse events were more frequent with AC-1202, primarily mild-to-moderate and transient gastrointestinal issues.

Study type
Randomized, double-blind, placebo-controlled trial
Who was studied
152 participants diagnosed with mild to moderate Alzheimer's disease
What was measured
Mean change from baseline in ADAS-Cog and global scores in ADCS-CGIC

THE PAPER

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Nutr Metab (Lond), 2009.

PubMed 19664276 ↗DOI 10.1002/gps.1168 ↗

Brain & moodHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.